Physician profile
Joshua R Shua Haim
NPI 1073554879
$44,703.91
in general payments reported to CMS, 2019-2025
33 companies · $8,774 in 2025
The $8,774 reported for 2025 was more than what 98% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,699 · 2020: $1,514 · 2021: $1,326 · 2022: $929 · 2023: $6,596 · 2024: $23K · 2025: $8,774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Travel and Lodging: $5,524 · Food and Beverage: $2,477 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,024.00 |
| Travel and Lodging | $5,523.88 |
| Food and Beverage | $2,476.75 |
| Education | $210.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $36,287.83 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $1,051.21 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,032.63 | 2019-2025 | Austedo Xr, Austedo Xr |
| Grifols Biologicals LLC | $746.71 | 2019 | |
| Acadia Pharmaceuticals INC | $614.70 | 2019-2025 | Nuplazid |
| Allergan, INC. | $571.21 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $565.45 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $564.36 | 2019-2024 | Spravato |
| Astrazeneca Pharmaceuticals Lp | $548.24 | 2019-2021 | |
| Abbvie INC. | $523.15 | 2021-2024 | Vraylar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $402.56 | 2022-2024 | Rexulti |
| Astellas Pharma US INC | $351.26 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $345.26 | 2020 | |
| Biogen, INC. | $200.00 | 2021-2022 | |
| Lilly USA, LLC | $199.09 | 2019-2024 | Kisunla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $150.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.60 | 2019-2020 | |
| Eisai INC. | $78.84 | 2022-2025 | |
| Novo Nordisk INC | $61.01 | 2019-2023 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $47.85 | 2020 | |
| Amarin Pharma, INC. | $44.74 | 2020 | |
| Vanda Pharmaceuticals INC. | $43.85 | 2019-2021 | |
| Acorda Therapeutics, INC | $41.36 | 2019 | |
| Ucb, INC. | $28.95 | 2022-2023 | Briviact |
| Merck Sharp & Dohme LLC | $28.20 | 2019 | |
| Alkermes, INC. | $14.66 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.52 | 2021 | |
| Ironwood Pharmaceuticals, INC | $14.04 | 2019 | |
| Neurocrine Biosciences, INC. | $13.79 | 2023 | Ingrezza |
| Nestle Healthcare Nutrition INC. | $12.82 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.19 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Shua Haim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.